Abstract
Experiments exploring the effect of fetal hemoglobin production in the mouse model of sickle cell disease will answer salient questions about the therapeutic potential of the controversial approach (177–182).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bunn, H.F. in The Molecular Basis of Blood Diseases 2nd edn. (eds. Stamatoyannopoulos, G., Niehhuis, A.W., Majerus, P.W. & Varmus, H.,) 207– 256 (W.B. Saunders, Philadelphia, Pennsylvania, 1994).
Blouin, M-J. et al. Genetic correction of sickle cell disease: Insights using transgenic mouse models. Nature Med. 6, 177–182 (2000).
Cole-Strauss, A. et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 273, 1386–1389 (1996).
Trudel, M. et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 10; 3157–3165 (1991).
Trudel, M. et al. Sickle cell disease of transgenic SAD mice. Blood 84, 3189–3197 ( 1994).
Nagel, R.L. A knockout of a transgenic mouse-Animal models of sickle cell anemia. N. Engl. J. Med. 339, 194–195 (1998).
Popp, R.L. et al. A transgenic mouse model of hemoglobin S Antilles disease. Blood 89, 4204–4212 ( 1997).
Fabry, M.E., Nagel, R.L., Pachnis, A., Suzuka, S.M. & Costantini, F. High expression of human βS and α-globins in transgenic mice: hemoglobin composition and hematological consequences . Proc. Natl. Acad. Sci. USA 89, 12150– 12154 (1992).
Kaul, D.K., Fabry, M.E., Costantini, F., Rubin, E.M. & Nagel, R.L. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J. Clin. Invest. 96, 194–195 (1998).
Paszty, C. et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278, 876 –878 (1997).
Ryan, T.M., Ciavatta, D.J. & Townes, T.M. Knockout-transgenic mouse model of sickle cell disease . Science 278, 873–876 (1997).
Mardiney, M. III et al. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood 89, 2268– 2275 (1997).
Bjorgvinsdottir, H. et al. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatous in murine X-linked chronic granulomatous disease. Blood 89, 41–48 ( 1997).
Pawliuk, R. et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nature Med. 5, 768–773 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karlsson, S. The first steps on the gene therapy pathway to anti-sickling success . Nat Med 6, 139–140 (2000). https://doi.org/10.1038/72227
Issue Date:
DOI: https://doi.org/10.1038/72227
